162 related articles for article (PubMed ID: 32702732)
1. Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform.
Chiuppesi F; Salazar MD; Contreras H; Nguyen V; Martinez J; Park S; Nguyen J; Kha M; Iniguez A; Zhou Q; Kaltcheva T; Levytskyy R; Ebelt N; Kang T; Wu X; Rogers T; Manuel E; Shostak Y; Diamond D; Wussow F
Res Sq; 2020 Jul; ():. PubMed ID: 32702732
[TBL] [Abstract][Full Text] [Related]
2. Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine.
Chiuppesi F; Salazar MD; Contreras H; Nguyen VH; Martinez J; Park S; Nguyen J; Kha M; Iniguez A; Zhou Q; Kaltcheva T; Levytskyy R; Ebelt ND; Kang TH; Wu X; Rogers T; Manuel ER; Shostak Y; Diamond DJ; Wussow F
bioRxiv; 2020 Jul; ():. PubMed ID: 32637957
[TBL] [Abstract][Full Text] [Related]
3. Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform.
Chiuppesi F; Salazar MD; Contreras H; Nguyen VH; Martinez J; Park Y; Nguyen J; Kha M; Iniguez A; Zhou Q; Kaltcheva T; Levytskyy R; Ebelt ND; Kang TH; Wu X; Rogers TF; Manuel ER; Shostak Y; Diamond DJ; Wussow F
Nat Commun; 2020 Nov; 11(1):6121. PubMed ID: 33257686
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.
García-Arriaza J; Garaigorta U; Pérez P; Lázaro-Frías A; Zamora C; Gastaminza P; Del Fresno C; Casasnovas JM; Sorzano CÓS; Sancho D; Esteban M
J Virol; 2021 Mar; 95(7):. PubMed ID: 33414159
[TBL] [Abstract][Full Text] [Related]
5. Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus.
Chiuppesi F; Zaia JA; Gutierrez-Franco MA; Ortega-Francisco S; Ly M; Kha M; Kim T; Dempsey S; Kar S; Grifoni A; Sette A; Wussow F; Diamond DJ
Commun Med (Lond); 2024 Feb; 4(1):19. PubMed ID: 38366141
[TBL] [Abstract][Full Text] [Related]
6. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
[TBL] [Abstract][Full Text] [Related]
7. CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in Mice.
Veit S; Jany S; Fux R; Sutter G; Volz A
Viruses; 2018 Dec; 10(12):. PubMed ID: 30558354
[TBL] [Abstract][Full Text] [Related]
8. Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice.
Zhu J; Wang Z; Li Y; Zhang Z; Ren S; Wang J; Xie S; Liao Z; Song B; Wu W; Yan F; Peng C
J Virol; 2024 Jun; ():e0052124. PubMed ID: 38874361
[TBL] [Abstract][Full Text] [Related]
9. Vaccinia Virus Strain MVA Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Glycoprotein Induces Robust Protection and Prevents Brain Infection in Mouse and Hamster Models.
Lorenzo MM; Marín-López A; Chiem K; Jimenez-Cabello L; Ullah I; Utrilla-Trigo S; Calvo-Pinilla E; Lorenzo G; Moreno S; Ye C; Park JG; Matía A; Brun A; Sánchez-Puig JM; Nogales A; Mothes W; Uchil PD; Kumar P; Ortego J; Fikrig E; Martinez-Sobrido L; Blasco R
Vaccines (Basel); 2023 May; 11(5):. PubMed ID: 37243110
[TBL] [Abstract][Full Text] [Related]
10. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
[TBL] [Abstract][Full Text] [Related]
11. MVA vector expression of SARS-CoV-2 spike protein and protection of adult Syrian hamsters against SARS-CoV-2 challenge.
Meseda CA; Stauft CB; Selvaraj P; Lien CZ; Pedro C; Nuñez IA; Woerner AM; Wang TT; Weir JP
NPJ Vaccines; 2021 Dec; 6(1):145. PubMed ID: 34862398
[TBL] [Abstract][Full Text] [Related]
12. Synthetic Multiantigen MVA Vaccine COH04S1 Protects Against SARS-CoV-2 in Syrian Hamsters and Non-Human Primates.
Chiuppesi F; Nguyen VH; Park Y; Contreras H; Karpinski V; Faircloth K; Nguyen J; Kha M; Johnson D; Martinez J; Iniguez A; Zhou Q; Kaltcheva T; Frankel P; Kar S; Sharma A; Andersen H; Lewis MG; Shostak Y; Wussow F; Diamond DJ
bioRxiv; 2021 Sep; ():. PubMed ID: 34545366
[TBL] [Abstract][Full Text] [Related]
13. Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.
Volz A; Sutter G
Adv Virus Res; 2017; 97():187-243. PubMed ID: 28057259
[TBL] [Abstract][Full Text] [Related]
14. MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans.
Mayer L; Weskamm LM; Fathi A; Kono M; Heidepriem J; Krähling V; Mellinghoff SC; Ly ML; Friedrich M; Hardtke S; Borregaard S; Hesterkamp T; Loeffler FF; Volz A; Sutter G; Becker S; Dahlke C; Addo MM
NPJ Vaccines; 2024 Jan; 9(1):20. PubMed ID: 38278816
[TBL] [Abstract][Full Text] [Related]
15. Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization.
Naito T; Kaneko Y; Kozbor D
J Gen Virol; 2007 Jan; 88(Pt 1):61-70. PubMed ID: 17170437
[TBL] [Abstract][Full Text] [Related]
16. An MVA Vector Expressing HIV-1 Envelope under the Control of a Potent Vaccinia Virus Promoter as a Promising Strategy in HIV/AIDS Vaccine Design.
Pérez P; Marín MQ; Lázaro-Frías A; Sorzano CÓS; Di Pilato M; Gómez CE; Esteban M; García-Arriaza J
Vaccines (Basel); 2019 Dec; 7(4):. PubMed ID: 31817622
[TBL] [Abstract][Full Text] [Related]
17. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
[TBL] [Abstract][Full Text] [Related]
18. Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates.
Chiuppesi F; Nguyen VH; Park Y; Contreras H; Karpinski V; Faircloth K; Nguyen J; Kha M; Johnson D; Martinez J; Iniguez A; Zhou Q; Kaltcheva T; Frankel P; Kar S; Sharma A; Andersen H; Lewis MG; Shostak Y; Wussow F; Diamond DJ
NPJ Vaccines; 2022 Jan; 7(1):7. PubMed ID: 35064109
[TBL] [Abstract][Full Text] [Related]
19. A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection.
Boulton S; Poutou J; Gill R; Alluqmani N; He X; Singaravelu R; Crupi MJF; Petryk J; Austin B; Angka L; Taha Z; Teo I; Singh S; Jamil R; Marius R; Martin N; Jamieson T; Azad T; Diallo JS; Ilkow CS; Bell JC
Mol Ther Methods Clin Dev; 2023 Dec; 31():101110. PubMed ID: 37822719
[TBL] [Abstract][Full Text] [Related]
20. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.
Wang Z; La Rosa C; Lacey SF; Maas R; Mekhoubad S; Britt WJ; Diamond DJ
J Clin Virol; 2006 Mar; 35(3):324-31. PubMed ID: 16388983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
